Notable Labs (VBLT) Stock Forecast, Price Target & Predictions
VBLT Stock Forecast
Notable Labs stock forecast is as follows: an average price target of $5.00 (represents a 3125.81% upside from VBLT’s last price of $0.15) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VBLT Price Target
The average price target for Notable Labs (VBLT) is $5.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 3125.81% upside from VBLT's last price of $0.15.
VBLT Analyst Ratings
According to 2 Wall Street analysts, Notable Labs's rating consensus is 'Buy'. The analyst rating breakdown for VBLT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Notable Labs Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 28, 2022 | - | Chardan Capital | $5.00 | $1.57 | 218.47% | 3125.81% |
The latest Notable Labs stock forecast, released on Apr 28, 2022 by Chardan Capital company, set a price target of $5.00, which represents a 218.47% increase from the stock price at the time of the forecast ($1.57), and a 3125.81% increase from VBLT last price ($0.15).
Notable Labs Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.15 | $0.15 | $0.15 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Notable Labs stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Notable Labs's last price of $0.15. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 20, 2022 | Morgan Stanley | - | Overweight | Upgrade |
| Apr 28, 2022 | Chardan Capital | - | Buy | Initialise |
Notable Labs's last stock rating was published by Morgan Stanley on Jul 20, 2022. The company Upgrade its VBLT rating from "null" to "Overweight".
Notable Labs Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VBLT | Notable Labs | $0.16 | $5.00 | 3025.00% | Buy |
| XFOR | X4 Pharmaceuticals | $0.50 | $3.67 | 634.00% | Buy |
| ATXI | Avenue Therapeutics | $2.00 | $12.00 | 500.00% | Buy |
| INZY | Inozyme Pharma | $5.28 | $14.67 | 177.84% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.93 | $38.80 | 159.88% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.70 | $7.00 | 159.26% | Buy |
| TERN | Terns Pharmaceuticals | $7.24 | $14.25 | 96.82% | Buy |
| ZURA | Zura Bio | $4.83 | $5.00 | 3.52% | Buy |
| HOOK | HOOKIPA Pharma | $3.99 | $3.00 | -24.81% | Buy |
VBLT Forecast FAQ
Is Notable Labs a good buy?
Yes, according to 2 Wall Street analysts, Notable Labs (VBLT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of VBLT's total ratings.
What is VBLT's price target?
Notable Labs (VBLT) average price target is $5 with a range of $5 to $5, implying a 3125.81% from its last price of $0.155. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Notable Labs stock go up soon?
According to Wall Street analysts' prediction for VBLT stock, the company can go up by 3125.81% (from the last price of $0.155 to the average price target of $5), up by 3125.81% based on the highest stock price target, and up by 3125.81% based on the lowest stock price target.
Can Notable Labs stock reach $0?
VBLT's average twelve months analyst stock price target of $5 supports the claim that Notable Labs can reach $0 in the near future.